MCL-1 is a prognostic indicator and drug target in breast cancerKirsteen J. Campbell, Karen Blyth|Cell Death and Disease|2018Cited by 202
<i>Runx2</i> and <i>MYC</i> Collaborate in Lymphoma Development by Suppressing Apoptotic and Growth Arrest Pathways <i>In vivo</i>Karen Blyth, Ewan R. Cameron|Cancer Research|2006Cited by 101
Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic functionKirsteen J. Campbell, Stephen W. G. Tait, Susan Mason et al.|Cell Death and Differentiation|2021Cited by 49
β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon CancerToshiyasu Suzuki, Seth B. Coffelt, Robert Wiesheu et al.|Cancer Immunology Research|2023Cited by 27
The RUNX/CBFβ Complex in Breast Cancer: A Conundrum of ContextAdiba Khan, Karen Blyth|Cells|2023Cited by 13